ILiAD Biotechnologies   Report issue

For profit Phase 2
Founded: New York NY United States (2012)

Organization Overview

First Clinical Trial
2019
NCT03942406
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ILiAD Biotechnologies

Active Ingredients

Drugs in Phase 2 Trials (2)

bpze1 (2 trials)

tdap-ipv vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Whooping Cough (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2